Trial intelligence / Profile preview

Liraglutide for Glucocorticoid Induced Hyperglycemia

NCT02016846Phase 3Unknown

Sponsor: Rabin Medical Center
Start: Jan 2014
Primary completion: Jan 2015
Modality: Peptides
Countries: 1

Overview

Phase 3, randomised, double-blind trial of liraglutide in glucocorticoid-induced hyperglycemia (GIDM) (2 arms), sponsored by Rabin Medical Center. Primary endpoint: Glucose levels 2 hours after 75 gr OGTT at 6 weeks. Status: unknown.

Drugs

liraglutide

Conditions

glucocorticoid-induced hyperglycemia (GIDM)

Beyond the preview

Go deeper on NCT02016846.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02016846.